Meeting
2024 ASCO Annual Meeting
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.
Authors
Yana Qi
Shandong Cancer Hospital and Institute, Jinan, China
Yana Qi , Yulan Sun , Hui Zhu , Hongbo Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8073)
DOI
10.1200/JCO.2024.42.16_suppl.8073
Abstract #
8073
Poster Bd #
335
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
First Author: yueyun chen
Poster
2023 ASCO Annual Meeting
Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
First Author: Jiyun Lee
Poster
2022 ASCO Annual Meeting
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
First Author: Emilia Cocorocchio
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner